Clinical Trials Directory

Trials / Suspended

SuspendedNCT07247292

Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia

A Multicenter Non-interventional Single-arm Retrospective-prospective Observational Study in Therapeutic Approaches on AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) in Real Clinical Practice in Russia

Status
Suspended
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
AstraZeneca · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.

Detailed description

This is a multicenter, retrospective-prospective, single-arm observational cohort study using secondary data collection from routine care medical records. The primary objective is to describe baseline demographic and clinical characteristics, diagnostic algorithms, and treatment approaches. Secondary objectives are to describe Expanded Disability Status Scale (EDSS) levels and dynamics, collect the rate, duration, and reasons for hospitalizations, and evaluate physician-reported relapse profiles. Approximately 100 adults will be enrolled consecutively across about 10 specialized sites. The study will sequentially include only those patients who have signed the informed consent form (ICF). Eligible patients will be enrolled consecutively at each site to minimize selection bias. Each participant will be followed for 36 months from informed consent (T0), with data collection every 6 months (T1-T6). The baseline period is defined as the time from NMOSD diagnosis until inclusion, with retrospective data abstraction; subsequent data are collected prospectively at routine visits. All data are entered into an electronic case report form (eCRF) from paper/electronic medical records. No study-specific interventions are performed; treatment is determined by usual care.

Conditions

Timeline

Start date
2025-12-23
Primary completion
2029-12-31
Completion
2029-12-31
First posted
2025-11-25
Last updated
2026-02-19

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT07247292. Inclusion in this directory is not an endorsement.